Pink SheetVyjuvek (beremagene geperpavec), Krystal Biotech’s topical gene therapy for the rare genetic skin disorder, dystrophic epidermolysis bullosa (DEB), could be approved for use across the EU soon, after
Pink SheetBeremagene geperpavec, Krystal Biotech’s topical gene therapy for the rare genetic skin disorder, dystrophic epidermolysis bullosa (DEB), is among the products that European Medicines Agency might thi
Pink SheetSeven new advanced therapy medicinal products (ATMPs) could be approved for pan-EU approval this year, based on data from the Pink Sheet’s EU regulatory filings tracker , including Roche / Sarepta
ScripLEO Pharma A/S is not saying for certain that it has closed the door on its ointment formulation of isotretinoin, but said on 21 August the failure of TMB-001 to hit the primary endpoint in a Phase I